Weiguang Bio announced on the morning of December 12 that the decision of Shenzhen Guangming New District Management Committee on the transfer of state-owned shares of Shenzhen Weiguang Biological Products Co., Ltd. without compensation was issued according to the Shenzhen Guangming New District Management Committee. Light Tube [2017] No. 59) and Shenzhen State-owned Assets Supervision and Administration Commission approved, in order to maintain the stability and management of Weiguang Biological, protect the interests of all shareholders, and implement the strategic planning of the Shenzhen Municipal Government, Guangming New District Management Committee on the operation structure of Guangming New District State-owned Assets The adjustment will be carried out, and the Guangming New District Management Committee will directly perform the duties of the investor.
The announcement said that after the change of the controlling shareholder of Weiguang Bio, the Guangming District Development and Finance Bureau directly held 70,470,000 shares of Weiguang Biological (accounting for 65.25% of the total share capital of Weiguang Bio), Guangming Group did not Then hold the shares of Weiguang Biological. As the Guangming District Development and Finance Bureau is the actual controller of the government department of Weiguang Biological, which is under the responsibility of the Shenzhen Guangming District People’s Government (formerly Shenzhen Guangming New District Management Committee), it is still the Guangming District of Shenzhen. People's Government (formerly Shenzhen Guangming New District Management Committee).
As of the announcement date, the acquisition still needs to be approved by the Shenzhen State-owned Assets Supervision and Administration Commission, and it is still necessary to obtain the approval of the China Securities Regulatory Commission to waive the purchaser's tender offer obligation.
Weiguang Bio said that before the implementation of the acquisition, the former Guangming New District Management Committee was a single shareholder of Guangming Group; Guangming Group held 70,470,000 shares of Weiguang Bio (accounting for 65.25% of Weiguang Bio's total share capital) , is the controlling shareholder of Weiguang Biological; Guangming New District Management Committee is the actual controller of Weiguang Biological. The purchaser Guangming District Development and Finance Bureau does not directly or indirectly hold shares in other Weiguang Biology.
The equity control relationship for the acquisition of Avantgarde Bio is as follows:
The acquisition method is the administrative transfer of state-owned shares. Shenzhen Guangming Group Co., Ltd. transferred its 65.25% stake in Shenzhen Weiguang Biological Products Co., Ltd. to Shenzhen Guangming District Development and Finance Bureau. . After the completion of the acquisition, Guangming District Development and Finance Bureau holds 65.25% of Weiguang Biological, and Guangming District Management Committee still holds 100% equity of Guangming Group.
The new equity control relationship of Weiguang Bio is as follows:
It is understood that Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985. It is a national high-tech enterprise, the only blood product manufacturer in Shenzhen, and the first state-owned listed company in Guangming New District, mainly engaged in the research and development and production of blood products. And sales.
Weiguang Bio has 9 kinds of products and 21 kinds of blood products production number, the main products include: human albumin, intravenous immunoglobulin (pH4), freeze-dried human immunoglobulin (pH4), human immunity Globulin, hepatitis B human immunoglobulin, rabies immunoglobulin, tetanus human immunoglobulin, histamine human immunoglobulin, human fibrinogen. It is one of the few companies in China that has three major categories of blood albumin, immunoglobulin and coagulation factors.
Weiguang Biomedical Industrial Park is located in Guangming New District of Shenzhen, adjacent to Sun Yat-sen University Shenzhen Campus and Guang'an New District Tian'an Yungu Industrial Park. The industrial park covers an area of ​​100 mu and has a planned total investment of 1.5 billion yuan. Weiguang Bio-Pharmaceutical Industrial Park is positioned as a new comprehensive bio-pharmaceutical industrial park, focusing on bio-pharmaceutical fields such as vaccines, recombinant proteins and medical devices. It integrates technology transformation, industrialization incubation, creator services and market development, and will become Shenzhen in the future. The base and center of important biomedical investment, entrepreneurship, R&D and manufacturing in the city and even in South China.
Thermoplastic starch is also called "non-structured starch", which can make the starch structure disordered and thermoplastic by certain methods. Starch molecules for polysaccharides molecular structure, containing a large number of hydroxyl, due to its intermolecular and intramolecular hydrogen bond action, so that its melting temperature is higher, and its decomposition temperature is lower than its melting temperature, so in the heat processing, starch molecules did not melt and first decomposed. The traditional mechanical processing method of plastic is mostly heat processing, so to make starch - based whole starch plastic needs to make natural starch thermoplastic. This thermoplasticity can be achieved by changing the crystalline structure inside starch molecules. Destroy intramolecular and intermolecular hydrogen bonds, disrupt the double helix crystal structure of starch molecules, which will reduce the melting temperature of starch and make it thermoplastic.
Starch-Based Plastics,Cellulose-Based Plastics,Protein-Based Plastics,Some Aliphatic Polyesters
Xingbang High Molecular Materials Co., Ltd. , https://www.chemicaladditive.com